Screener Summaries Updates Institutions Sign In More Updates › Mergers & Acquisitions › SDGR Mergers & Acquisitions · Jun 29, 2026
Schrödinger receives $57M from Eli Lilly's acquisition of Ajax Therapeutics SDGR Schrodinger, Inc.
Schrödinger, Inc. received approximately $57 million in cash following Eli Lilly and Company's acquisition of Ajax Therapeutics, Inc., a company co-founded by the registrant. The Company is also eligible for additional cash payments contingent upon Ajax achieving specific clinical and regulatory milestones. Schrödinger, Inc. is a software-based drug discovery company.
More from Schrodinger, Inc. Reports Q3 net loss of $37.7M on $64.5M revenue, raises full-year outlook Nov 4, 2026 Schrödinger reports Q2 revenue of $58.9M, up 8%, with net income of $6.0M aided by $45.9M investment gain Aug 5, 2026 At its 2026 Annual Meeting of Stockholders on June 22, 2026, Schrödinger, Inc. stockholders approved an amendment to… Jun 23, 2026 Schrodinger agrees to pay former CCO $88,096 in prorated bonus plus salary continuation under separation deal Jun 8, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
